PD-L1 is a widely used biomarker for cancer patient selection for checkpoint inhibitors, a class of cancer drugs representing ...

Ultimately, the research showed that immune cells need physical as well as chemical cues to properly manage PD-1 activity, ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

Adding PD-(L)1 inhibitors to chemotherapy improved outcomes, but PD-(L)1 inhibitors alone were no more effective than chemotherapy alone in patients with gastric, gastroesophageal junction, and ...

Researchers from Zhejiang Jieyuan Med-Tech Co. Ltd. and collaborators have reported the design and preclinical characterization of a novel series of benzylamine derivatives acting as PD-1/PD-L1 ...

Keay Nakae, an analyst from Chardan Capital, maintained the Buy rating on Arbutus Biopharma (ABUS – Research Report). The associated ...

Joshua K. Sabari, MD, discusses the anticipated clinical benefits of adding tarlatamab to durvalumab as maintenance therapy ...

Arbutus Biopharma Corp (ABUS) showcases significant progress in hepatitis B treatment and maintains a robust cash runway into 2026.

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...